Disease Landscape and Forecast 인사이트

Clarivate Epidemiology’s coverage of RAS comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of acute musculoskeletal pain (AMP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States…

Clarivate Epidemiology’s coverage of the shingles vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of the hepatitis B virus (HBV) vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Clarivate Epidemiology’s coverage of minor depression comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total prevalence of minor…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key minor depression patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of minor depression comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of minor depression for…

Immune checkpoint inhibitors have greatly altered the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to treatment of advanced disease, the…

Clarivate Epidemiology’s coverage of dry eye disease (DED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of epidermal growth factor receptor (EGFR)-mutated tumors comprises epidemiological estimates of key patient populations with the biomarker in the major mature…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pulmonary hypertension disease patient populations, covering 171…

Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets. We report the…